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Background: Mutations in the chloroquine resistance transporter (PfCRT) change the susceptibility of Plasmodium fal-
ciparum to diverse antimalarial drugs.
Results: In addition to chloroquine, PfCRT transports quinine, quinidine, and verapamil, which bind to distinct but antagonis-
tically interacting sites.
Conclusion: PfCRT is a multidrug carrier with a polyspecific drug-binding cavity.
Significance: These findings could be used to develop high affinity inhibitors of PfCRT.
Mutations in the “chloroquine resistance transporter” (PfCRT)
are a major determinant of drug resistance in the malaria
parasite Plasmodium falciparum. We have previously shown
that mutant PfCRT transports the antimalarial drug chloro-
quine away from its target, whereas the wild-type form of
PfCRT does not. However, little is understood about the
transport of other drugs via PfCRT or the mechanism by
which PfCRT recognizes different substrates. Here we show
that mutant PfCRT also transports quinine, quinidine, and
verapamil, indicating that the protein behaves as a multidrug
resistance carrier. Detailed kinetic analyses revealed that
chloroquine and quinine compete for transport via PfCRT in
a manner that is consistent with mixed-type inhibition.
Moreover, our analyses suggest that PfCRT accepts chloro-
quine and quinine at distinct but antagonistically interacting
sites. We also found verapamil to be a partial mixed-type
inhibitor of chloroquine transport via PfCRT, further sup-
porting the idea that PfCRT possesses multiple substrate-
binding sites. Our findings provide new mechanistic insights
into the workings of PfCRT, which could be exploited to
design potent inhibitors of this key mediator of drug
resistance.
Changes in the “chloroquine resistance transporter”
(PfCRT)5 are associated with reductions in the susceptibility of
the human malaria parasite Plasmodium falciparum to several
important antimalarial drugs (1, 2). Initially identified as the
main determinant of resistance to chloroquine (3), a synthetic
4-aminoquinoline and a mainstay in previous campaigns to
eradicate malaria, mutations in PfCRT are now known to have
wide-ranging effects on the parasite’s sensitivity to an assort-
ment of pharmacons (4). These include antimalarial drugs that
share the quinoline scaffold (e.g. quinine, amodiaquine, and
mefloquine) or that possess structural moieties present in quin-
oline drugs (e.g. lumefantrine and halofantrine) but also
encompass a diverse range of compounds that have not been
deployed as antimalarial treatments (4 –12). Given that the
activities of most of the antimalarials that currently serve as
partner drugs in the artemisinin-based combination thera-
pies are affected by mutations in PfCRT (1) and that all of the
upcoming partner drugs are quinolines or quinoline-related,
it is possible that PfCRT may evolve multidrug resistance
capabilities that will render entire drug classes ineffective,
including compounds that are in clinical and preclinical
development. It is vital that we prolong the longevity and
efficacy of the current quinoline drugs and also retard the
emergence and spread of resistance to new antimalarials. A
greater understanding of the mechanism by which PfCRT
alters the parasite’s susceptibility to diverse compounds
could form the basis for antimalarial strategies that combat
PfCRT-mediated drug resistance.
PfCRT is a member of the drug/metabolite transporter
superfamily and displays the 2-fold pseudosymmetry typical of
carriers (13). The transporter resides at the membrane of the
parasite’s digestive vacuole (3) and is thought to efflux drugs out
of this organelle, away from their main target, the detoxification
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of heme arising from the digestion of host hemoglobin (1, 2, 14).
Evidence of PfCRT functioning as a drug carrier has come from
in vitro parasite assays as well as characterizations of PfCRT in
heterologous expression systems. In the parasite studies, the
efflux of radiolabeled drugs from parasite-infected red blood
cells was linked to PfCRT (15–18), and PfCRT was also impli-
cated in the drug-mediated efflux of protons from the digestive
vacuole of chloroquine-resistant parasites (19 –21). Moreover,
heterologous expression of the Dd2 form of PfCRT (PfCRTDd2)
at endosomal membranes within Dictyostelium discoideum
reduced the accumulation of chloroquine and quinine within
these vesicles, consistent with the mutant protein mediating
the transport of these two drugs (22, 23). Finally, a diverse range
of chloroquine-resistant variants of PfCRT induced saturable
chloroquine transport when expressed at the surface of Xeno-
pus laevis oocytes (24, 25). By contrast, the wild-type form of
the protein (found in chloroquine-sensitive parasites) did not
exhibit chloroquine transport activity in this assay. A key
advantage of the oocyte system is that it allows interactions
with PfCRT to be studied directly and in isolation, without con-
founding effects such as the binding of drugs to heme or to
other targets or transporters within the parasite-infected red
blood cell.
Although it is now well established that chloroquine-resis-
tant forms of PfCRT transport chloroquine, little is known
about its ability to mediate the transport of other drugs or how
the protein recognizes diverse compounds. For instance, it is
unclear whether PfCRT accepts different drugs at a single site
or at distinct sites. Several lines of evidence support the view
that PfCRT possesses a single drug-binding site, with the lysine
to threonine mutation at position 76 (K76T) playing a pivotal
role in the binding and translocation of drugs (26, 27). Indeed,
all chloroquine-resistant field isolates identified to date harbor
a mutation at position 76, and reversal of the K76T mutation
has been shown to abolish the transport of chloroquine via
resistant forms of PfCRT (15, 24, 25) and to increase the para-
site’s susceptibility to a number of drugs, including chloro-
quine, quinine, and amodiaquine (28, 29). On the other hand,
the fact that PfCRT variants of different geographic origins vary
in both the number (typically 4 –10 amino acid substitutions)
and nature of the mutations they contain and that such varia-
tions may impart different drug responses (7, 8) suggests that a
more complex interaction may exist between PfCRT and its
drug substrates.
Here we investigated the interaction of PfCRT with chloro-
quine, quinine, quinidine, and verapamil. The latter compound
can partially reverse chloroquine resistance in vitro (30). The
PfCRTDd2 variant of the protein (from the Southeast Asian
strain Dd2, which is chloroquine-resistant and also exhibits
reduced sensitivity to quinine) was expressed in Xenopus
oocytes and shown to mediate the transport of radiolabeled
chloroquine, quinine, quinidine, and verapamil. The results of
an in depth kinetic examination of the inhibition of chloroquine
or quinine transport by another drug suggest that PfCRTDd2
possesses at least two distinct binding sites that antagonistically
affect one another.
EXPERIMENTAL PROCEDURES
Ethical Statement—Ethical approval of the work performed
with the X. laevis frogs was obtained from (i) the Australian
National University Animal Experimentation Ethics Commit-
tee (Animal Ethics Protocol Number A2013/13) in accordance
with the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes and (ii) the Regierungsprä-
sidium Karlsruhe (Aktenzeichen 35-9185 81/G-31/11) in
accordance with the German “Tierschutzgesetz.”
Radiolabeled Drugs—[3H]Chloroquine (specific activity,
5–25 Ci mmol1), [3H]quinine (specific activity, 10 –20 Ci
mmol1), [3H]quinidine (specific activity, 5–25 Ci mmol1),
and [3H]verapamil (specific activity, 80 Ci mmol1) were
obtained from American Radiolabeled Chemicals or GE
Healthcare.
Harvesting of Xenopus Oocytes and Expression of PfCRT—
Adult female X. laevis frogs (purchased from NASCO) were
anesthetized by submersion in a solution of 0.1% (w/v) ethyl
3-amino benzoate methanesulfonate and 1 mM NaCO3 for
15–20 min. Sections of the ovary were surgically removed and
placed in Ca2-free amphibian-adapted Ringer’s solution (96
mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.5)
supplemented with penicillin/streptomycin (10 mg/ml). The
collagenous membrane that envelopes the oocyte lobes, as well
as the individual oocytes, was removed by the addition of col-
lagenase D (final concentration of 0.3 FALGPA units/ml). Fol-
lowing collagenase treatment, the oocytes were kept in Ca2-
replete amphibian-adapted Ringer’s solution (96 mM NaCl, 2
mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES, pH 7.5)
supplemented with penicillin/streptomycin (10 mg/ml). Expres-
sion of the HB3 and Dd2 versions of PfCRT at the plasma mem-
brane of Xenopus oocytes was achieved as described previously
(24, 25). Briefly, cRNA was transcribed in vitro using a mMes-
sage mMachine kit (Ambion) and microinjected into stage
V-VI oocytes (30 ng/oocyte). Oocytes were incubated for
48 –72 h at 18 °C in ND96 medium (96 mM NaCl, 2 mM KCl, 1.8
mM CaCl2, 1 mM MgCl2, 10 mM MES, and 10 mM Tris, pH 7.5),
and water-injected oocytes served as a negative control.
Drug Transport Assays—Measurements of radiolabeled drug
uptake were made over 1 h at 25 °C and in a ND96 medium that
contained [3H]chloroquine (50 nM), [3H]quinine (62.5 nM),
[3H]quinidine (62.5 nM), or [3H]verapamil (25 nM). Where
specified, one or more unlabeled drugs were present at the indi-
cated concentrations. The influx assays were terminated by
removing the reaction medium and washing the oocytes three
times with 3 ml of ice-cold ND96 buffer. Each oocyte was trans-
ferred to a separate scintillation vial and lysed by the addition of
5% sodium dodecyl sulfate (200 l). The radioactivity in the
sample solution was measured using a -scintillation counter.
The direction of radiolabeled drug transport in these assays is
from the acidic extracellular medium (in most cases pH 6.0, and
pH 4.0, 4.5, 5.0, or 5.5 where indicated) into the oocyte cytosol
(pH 7.2), which corresponds to the efflux of drug from the
acidic digestive vacuole (pH 5–5.5) into the parasite cytosol (pH
7.3). Water-injected oocytes and oocytes expressing PfCRTHB3
take up [3H]chloroquine to similar (low) levels via simple diffu-
sion of the neutral species; this represents the “background”
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level of chloroquine accumulation in oocytes (see Ref. 24 for full
data and a detailed discussion). PfCRTDd2-mediated drug
transport was calculated by subtracting the uptake measured in
water-injected oocytes from that in oocytes expressing
PfCRTDd2. Where specified, statistical comparisons were made
with Student’s t test for paired samples or with analysis of vari-
ance in conjunction with Tukey’s multiple comparisons test.
The half-maximum inhibitory concentrations derived from
Figs. 3, 5, and 9 (A and B) were obtained by least-squares fit of
the equation, Y  Ymin  ((Ymax  Ymin)/(1  ([inhibitor]/
IC50)C), where Y is PfCRTDd2-mediated drug transport, Ymin
and Ymax are the minimum and maximum values of Y, IC50 is
the half-maximum inhibitory concentration, and C is a
constant.
Discrimination between Models and Statistical Analyses of
the Kinetic Data—Analyses of the kinetic data were performed
using Sigma Plot version 12.5 and the software package “R” (31).
The 16 different inhibition models (32) were globally fitted to
the kinetic data using the least-squares method. The models
were then ranked according to their Akaike information crite-
rion difference (AICc) and their Akaike weight using a method
described previously (33, 34). The two top-ranked models were
compared using an F-test.
The Akaike information criterion (AICc) of the ith model
(AICci) was calculated according to Equation 1,
AICc  n  lnRSSn   2  K  2  K  K  1n  K  1
(Eq. 1)
where RSS is the residual sum of squares.
RSS  
i  1
n
 yi  ŷi
2 (Eq. 2)
Here, n is the total number of measurements used to perform
the global fit, yi are the experimentally measured values, ŷi are
the values predicted by the model, and K is the number of
parameters in the model. The AICc of the ith model (i) was
then calculated according to Equation 3,
 i  AICc
i  AICc
min (Eq. 3)
where AICcmin is the smallest AICc value of all of the models
tested. Models with AICc 	 2 are equally plausible, models with
4 	 AICc 	 7 are considerably less likely, and models with
AICc 
 10 are considered unlikely (33).
For a more detailed evaluation of the plausibility of models,
the Akaike weight (wi) was calculated according to Equation 4,
wi 
exp1
2
 i
k  1K exp12  k
(Eq. 4)
where i is as described above, k is the AICc difference of
the kth model investigated, and K is the total number of models
investigated. wi can be in the interval of 0  wi  1 and reports the
plausibility of the model. The model with the highest Akaike
weight (i.e. closest to 1) is considered to be the best fit to the data.
The F statistic was calculated according to Equation 5,
F 
RSS1  RSS2
RSS2

n  p1
p2  p1
(Eq. 5)
where RSS1 and RSS2 are given by Equations 6 and 7,
RSS1  
i  1
n
 yi  ŷi
2 (Eq. 6)
RSS2  
k  1
n
 yk  ŷk
2 (Eq. 7)
where RSS1 is the residual sum of squares of the first model,
RSS2 is the residual sum of squares of the second model, yi and
yk are the experimentally determined values for the first and
second models respectively, and ŷi and ŷk are the predicted val-
ues for the first and second models. n is the total number of data
points, and p1 and p2 are the number of parameters present in
the first and second models, respectively. The p value of the
corresponding F statistics and its degrees of freedom were cal-
culated using R. p 	 0.05 indicates that the model with fewer
parameters fits the data significantly better than the model with
more parameters. All analyses of the kinetic data were performed
using Sigma Plot version 12.5 or the software package R (31).
Equations Describing 16 Different Kinetic Models—The fol-
lowing kinetic equations were adapted from Segel (32). The
concentration of substrate 1 is denoted as [S1] and the concen-
tration of the second, inhibiting substrate is denoted as [S2]. KS1
and KS2 are the dissociation constants for the respective sub-
strate-protein complexes. Full mixed-type (linear mixed-type)
inhibition is given by Equation 8.
v 
Vmax
S1
KS1
1 
S1
KS1

S2
KS2

S1S2
	KS1KS2
(Eq. 8)
Partial mixed-type (hyperbolic mixed-type) inhibition is given
by Equation 9.
v 
VmaxS1KS1  S1S2	KS1KS2 
1 
S1
KS1

S2
KS2

S1S2
	KS1KS2
(Eq. 9)
Full competitive inhibition is given by Equation 10.
v 
Vmax
S1
KS
1 
S1
KS1

S2
KS2
(Eq. 10)
Partial competitive inhibition is given by Equation 11.
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v 
VmaxS1KS1  S1S2	KS1KS2 
1 
S1
KS1

S2
KS2

S1S2
	KS1KS2
(Eq. 11)
Full noncompetitive inhibition is given by Equation 12.
v 
Vmax
S1
KS1
1 
S1
KS1

S2
KS2

S1S2
KS1KS2
(Eq. 12)
Partial noncompetitive inhibition is given by Equation 13.
v 
VmaxS1KS1  S1S2KS1  KS2
1 
S1
KS1

S2
KS2

S1S2
KS1KS2
(Eq. 13)
Full uncompetitive inhibition is given by Equation 14.
v 
Vmax
S1
KS1
1 
S1
KS1

S1S2
KS1KS2
(Eq. 14)
Partial uncompetitive inhibition is given by Equation 15.
v 
VmaxS1
KS1
1  S2KS2 
 S1
1  S2KS2 
1  S2KS2 
(Eq. 15)
Ligand exclusion is given by Equation 16.
v 
VmaxS1KS1  S1
2
KS1
2 
1 
2S1
KS1

S12
KS1
2 
S2
KS2
(Eq. 16)
Cooperative substrate binding is given by Equation 17.
v 
VmaxS1KS1  S1
2
aKS1
2 
S1S2
aKS1KS2

1 
2S1
KS1

S12
aKS1
2 
2S1S2
aKS1KS2

2S2
KS2

S22
aKS2
2
(Eq. 17)
In cooperative substrate binding, the inhibitor does not mimic
the substrate. This case is asymmetric; hence, there are differ-
ent equations for the substrate (Equation 18) and the inhibitor
(Equation 19).
v 
VmaxS1KS1  S1
2
aKS1
2 
S1S2
KS1KS2

1 
2S1
KS1

S12
aKS1
2 
2S1S2
KS1KS2

2S2
KS2

S22
KS2
2
(Eq. 18)
v 
VmaxS1KS1  S1
2
KS1
2 
S1S2
KS1KS2

1 
2S1
KS1

S12
KS1
2 
2S1S2
KS1KS2

2S2
KS2

S22
cKS2
2
(Eq. 19)
Two-site pure competitive inhibition is given by Equation 20.
v 
VmaxS1KS1  S1
2
aKS1
2 
S1S2
bKS1KS2

1 
2S1
KS1

S12
aKS1
2 
2S1S2
bKS1KS2

2S2
KS2

S22
cKS2
2
(Eq. 20)
Partial competitive inhibition is given by Equation 21.
v 
VmaxS1KS1  S1
2
aKS1
2 
S2S1
	KS2KS1

S2S12
a	2KS2KS1
2
1 
2S1
KS1

S12
aKS1
2 
S2
KS2

2S2S1
	KS2KS1

S2S12
a	2KS2KS1
2
(Eq. 21)
For substrate non-cooperative in the absence of inhibitor, the
substrate reverses the effect of the inhibitor.
v 
VmaxS1KS1  S1
2
KS1
2 
S1S2
	KS1KS2

S12S2
	KS1
2KS2

1 
2S1
KS1

S12
KS1
2 
S2
KS2

2S1S2
	KS1KS2

S12S2
	KS1
2KS2
(Eq. 22)
For substrate cooperative in the absence of the inhibitor, the
substrate reverses the effect of the inhibitor.
v 
VmaxS1KS1  S1
2
aKS1
2 
S1S2
	KS1KS2

S12S2
a	KS1
2KS2

1 
2S1
KS1

S12
aKS1
2 
2S1S2
	KS1KS2

S12S2
a	KS1
2KS2

S2
KS2
(Eq. 23)
Inhibitor eliminates substrate cooperativity.
v 
VmaxS1KS1  S1
2
aKS1
2 
S1S2
KS1KS2

S12S2
KS1
2KS2

1 
2S1
KS1

S12
aKS1
2 
2S1S2
KS1KS2

[S1]2S2
KS1
2KS2

S2
KS2
(Eq. 24)
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Competition Plot—The competition plot was performed as
described elsewhere (35). Briefly, the substrate with the lower
Vmax was termed “A” (in this case quinine), and the substrate
with the higher Vmax was termed “B” (in this case chloroquine).
A concentration of chloroquine (from the 0 M quinine treat-
ment of Fig. 2A) and a concentration of quinine (from the 0 M
chloroquine treatment of Fig. 4A) were selected, such that (i)
the rate of chloroquine transport was equivalent to the rate of
quinine transport, and (ii) the transport rate for quinine (which
was the less efficiently transported substrate) approached its
Vmax (9.3  0.2 pmol of quinine/h/oocyte). The resulting con-
centrations were a0  73.5 M and b0  52.1 M for quinine and
chloroquine, respectively. At these concentrations of quinine
and chloroquine, va  vb  7.4 pmol/h/oocyte. A series of reac-
tion buffers containing A and B at concentrations a  (1  P) 
a0 and b  P  b0 were assembled (with 0  P  1). For each of
these mixtures, the individual velocities va and vb, as well as
with the total rate of drug transport (Vtotal  va  vb), were
predicted from the kinetic data presented in Figs. 2A and 4A.
The resulting values are presented in Table 1. The rates of chlo-
roquine and quinine transport were then measured in pairwise
experiments by the addition of either [3H]chloroquine or
[3H]quinine to each of the unlabeled chloroquine/quinine mix-
tures (boldface type in Table 1). These corresponded to P values
of 0, 0.15, 0.4, 0.6, 0.9, and 1.0. A plot of P as a function of Vtotal
yielded the competition plot.
RESULTS
PfCRTDd2 Mediates the Saturable Transport of Quinine
and Quinidine—Quinine and its stereoisomer quinidine are
diprotic weak bases with pKa values of 4.12 and 8.58 and 4.42
and 8.58, respectively (where Ka is the acid dissociation
constant). Both drugs can permeate membranes as free bases
and will partition between membrane-bound compartments
according to the prevailing pH gradient. The uptake of radiola-
beled quinine and quinidine was measured in an acidic medium
(pH 5.0) into Xenopus oocytes expressing either PfCRTDd2 or
the wild-type protein from the HB3 strain (PfCRTHB3) as well as
into water-injected oocytes. Oocytes expressing PfCRTDd2
took up significantly more quinine and quinidine relative to
water-injected oocytes or oocytes expressing PfCRTHB3 (left
panels of Fig. 1, A and B, respectively). Similar results were
obtained when the time courses were performed at pH 6.0 (data
not shown). The level of uptake in oocytes expressing
PfCRTHB3 was not significantly different from that measured in
water-injected oocytes, indicating that the accumulation of
quinine and quinidine in these oocytes and in the water-in-
jected oocytes was most likely due to the simple diffusion of the
uncharged forms of these drugs. Consistent with this observa-
tion, quinine transport was shown to be dependent on the pH of
the medium (Fig. 1C). That is, the accumulation of quinine in
the control oocytes increased as the pH was raised from 4.0 to
6.0, which correlated well with the pH dependence of the con-
centration of the uncharged quinine present in the medium
(Fig. 1D). Nevertheless, under each of the conditions tested, the
accumulation of quinine in oocytes expressing PfCRTDd2 was
significantly higher than that measured in water-injected
oocytes and in oocytes expressing PfCRTHB3 (p 	 0.05).
The portion of quinine or quinidine accumulation attributa-
ble to PfCRTDd2 was calculated by subtracting the uptake
in oocytes expressing PfCRTHB3 from that measured in
PfCRTDd2-expressing oocytes (middle panels of Fig. 1, A and B,
respectively). The resulting data indicated that the PfCRTDd2-
mediated uptake of quinine and quinidine was approximately
linear with time for at least 60 min at both pH 5.0 and pH 6.0.
We also tested the ability of the resistance reverser verapamil
to inhibit the uptake of quinine and quinidine via PfCRTDd2 at
pH 5.0 (Fig. 1E). Verapamil has previously been shown to
inhibit chloroquine transport via PfCRTDd2 (24), and consis-
tent with this activity, the addition of 100 M verapamil signif-
icantly reduced the PfCRTDd2-mediated uptake of quinine and
quinidine.
Given that the time dependence of PfCRTDd2-mediated
uptake at pH 6.0 was roughly comparable to that obtained at pH
5.0, and in order to facilitate comparisons with previous kinetic
analyses of transport via PfCRTDd2 (which were performed at
pH 6.0 (24, 25)), the saturability of quinine and quinidine trans-
port was determined at pH 6.0. For both quinine and quini-
dine, the uptake of radiolabeled drug in PfCRTDd2-express-
ing oocytes decreased with increasing concentrations of the
unlabeled drug, consistent with transport occurring via a
saturable mechanism (right panels of Fig. 1, A and B, respec-
tively). A least squares fit of the Michaelis-Menten equation
to the data yielded apparent Michaelis constants (Km) of
28  4 and 23  4 M and maximal velocities (Vmax) of 14 
1 and 13  1 pmol/h/oocyte for quinine and quinidine,
respectively.
Chloroquine and Quinine are Mixed-type Inhibitors of
PfCRTDd2—The finding that PfCRTDd2 transports both quinine
and chloroquine led us to undertake a series of kinetic analyses
to assess the mechanism by which PfCRT accepts different sub-
strates. Substrate competition experiments were conducted in
TABLE 1
Predicted rates of quinine, chloroquine, and total drug transport in
the presence of different concentrations of quinine and chloroquine
Quinine is denoted as substrate A and chloroquine as substrate B. P is the propor-
tion of quinine in the chloroquine/quinine mixture, va and vb, are the respective
rates of quinine and chloroquine transport, and Vtotal is the sum of va and vb. The
values for va and vb were calculated from the kinetic data presented in Figs. 2A and
4A.
P va vb Vtotal Quinine Chloroquine
pmol/h/oocyte pmol/h/oocyte pmol/h/oocyte M M
0.00 7.40 0.00 7.40 73.50 0.00
0.05 5.79 0.11 5.90 69.83 2.61
0.10 5.67 0.24 5.91 66.15 5.21
0.15 5.54 0.37 5.91 62.48 7.82
0.20 5.41 0.51 5.91 58.80 10.42
0.25 5.26 0.66 5.92 55.13 13.03
0.30 5.11 0.82 5.93 51.45 15.63
0.35 4.94 1.00 5.94 47.78 18.24
0.40 4.76 1.19 5.95 44.10 20.84
0.45 4.56 1.40 5.96 40.43 23.45
0.50 4.34 1.64 5.98 36.75 26.05
0.55 4.11 1.91 6.02 33.08 28.66
0.60 3.84 2.20 6.05 29.40 31.26
0.65 3.54 2.54 6.09 25.73 33.87
0.70 3.21 2.92 6.13 22.05 36.47
0.75 2.80 3.37 6.17 18.38 39.08
0.80 2.34 3.90 6.24 14.70 41.68
0.85 1.84 4.53 6.37 11.03 44.29
0.90 1.29 5.30 6.60 7.35 46.89
0.95 0.69 6.25 6.94 3.68 49.50
1.00 0.00 7.40 7.40 0.00 52.10
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which the uptake of radiolabeled chloroquine was determined
at 60 min (i.e. within the initial phase of chloroquine uptake
(24)) in water-injected oocytes and oocytes expressing
PfCRTDd2. In these assays, the extracellular medium contained
one of seven concentrations of unlabeled chloroquine (ranging
from 10 to 500 M), and at each of these chloroquine concen-
trations, the effects of seven concentrations of unlabeled qui-
nine (ranging from 0 to 500 M) were tested. The rate of PfCRT-
mediated chloroquine uptake was calculated, and each of the
seven quinine data sets was plotted as a function of the chloro-
quine concentration (Fig. 2A). To determine the nature of the
interaction between PfCRT, chloroquine, and quinine, we per-
FIGURE 1. The transport of quinine and quinidine into Xenopus oocytes expressing PfCRT. A and B, PfCRTDd2 mediates quinine (QN) and quinidine (QD)
uptake, respectively. Left panels, time courses for the uptake of quinine and quinidine into water-injected oocytes (solid circles) and oocytes expressing
PfCRTHB3 (triangles) or PfCRTDd2 (solid squares). The extracellular pH was 5.0, and the total concentration of the drug (radiolabeled plus unlabeled) was 10 M.
Middle panels, PfCRTDd2-mediated uptake of quinine or quinidine at pH 5.0 and 6.0. The PfCRTDd2-mediated component of transport was obtained by sub-
tracting uptake in oocytes expressing PfCRTHB3 from that measured in PfCRTDd2-expressing oocytes. Right panels, concentration dependence of the PfCRTDd2-
mediated uptake of quinine and quinidine. In both cases, the uptake of radiolabeled drug into water-injected oocytes and oocytes expressing PfCRTDd2 was
measured at pH 6.0 over an extracellular concentration range of 0.05–100 M drug (radiolabeled plus unlabeled). The rate of PfCRTDd2-mediated transport was
calculated by subtracting the rate measured in water-injected oocytes from that in oocytes expressing PfCRTDd2 at each quinine or quinidine concentration. A
least-squares fit of the Michaelis-Menten equation to the resulting data (using Sigma Plot version 12.5) yielded the following kinetic parameters: quinine,
apparent Km  28  4 M and apparent Vmax  14  1 pmol/h/oocyte; quinidine, Km  23  4 M and apparent Vmax  13  1 pmol/h/oocyte. C, pH
dependence of quinine uptake into water-injected oocytes and oocytes expressing PfCRTHB3 or PfCRTDd2. Measurements of radiolabeled quinine transport
were made over the extracellular pH range (pH 4.0 – 6.0) and in the presence of 1 M unlabeled quinine. Asterisks indicate significant differences in the
accumulation of quinine between the control (water-injected or PfCRTHB3-expressing) oocytes and oocytes expressing PfCRTDd2 within each pH condition (*,
p 	 0.05). D, percentages of quinine in the neutral (QN), monoprotonated (QN), and diprotonated (QN2) forms in solutions of different pH. The percentages
were calculated using the Henderson-Hasselbalch equation, with pKa values of 4.12 for the quinoline nitrogen and 8.58 for the side chain nitrogen (51). E, the
effect of verapamil (100 M) on the PfCRTDd2-mediated transport of quinine (black bars) and quinidine (gray bars) was measured at pH 5.0. The total extracellular
concentration of quinine or quinidine (radiolabeled plus unlabeled) was 10 M. Asterisks indicate significant differences in the PfCRTDd2-mediated uptake of
radiolabeled drug between the control oocytes and those suspended in 100 M verapamil (*, p 	 0.05). In all cases, uptake is shown as the mean  S.E. (error
bars) of at least three biological repeats, within which measurements were made from 10 oocytes/treatment.
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formed a least-squares global fit of 16 different models of inhi-
bition (32) to the data. The inhibition models were then ranked
according to two measures that reflect how well a given model
explains the experimentally derived data: the second-order
Akaike information criterion difference (AICc) and the Akaike
weight (33) (Fig. 2B). The resulting rankings were assessed
using the heuristic criteria devised by Burnham and Anderson
(33), in which models with AICc 	 2 are equally plausible,
models with 4 	 AICc 	 7 are considerably less likely, and
models with AICc 
 10 are considered unlikely. The Akaike
weight varies from 1 to 0, with the plausibility of the model
increasing as the Akaike weight approaches 1. According to
these analyses, the most plausible models for the binding of
quinine to PfCRT were full mixed-type inhibition followed by
partial mixed-type inhibition (Fig. 2B and Table 2). The respec-
tive values for AICc (0 and 2.0) suggested that both models
were equally credible. We therefore applied an F-test to dis-
criminate between full mixed-type inhibition and partial
mixed-type inhibition, the results of which indicated that the
former model provided the better fit to the data (F  0.5; p 	
0.01).
The models ranked third and fourth were full and partial
noncompetitive inhibition, respectively. Although the Akaike
weights for these two models were low, the AICc values (which
were between 3 and 6) indicated that neither model could be
immediately dismissed. However, cases of noncompetitive
FIGURE 2. Kinetic analysis of the inhibition of PfCRTDd2-mediated chloroquine transport by quinine. A, the uptake of chloroquine (CQ) into water-injected
oocytes and oocytes expressing PfCRTDd2 was measured at pH 6.0 and in the presence of a total extracellular chloroquine concentration (radiolabeled plus
unlabeled) of 10, 50, 100, 200, 300, 400, or 500 M. At each of these chloroquine concentrations, the effects of seven concentrations of unlabeled quinine (QN;
ranging from 0 to 500 M) were tested. For each of the 49 treatments, the rate of chloroquine transport attributable to PfCRTDd2 was then calculated by
subtracting the rate measured in water-injected oocytes from that in oocytes expressing PfCRTDd2. Chloroquine uptake is shown as the mean  S.E. (error bars)
of at least three biological repeats, within which measurements were made from 10 oocytes/treatment. B, Sixteen different models of inhibition were globally
fitted to the data presented in A using the least-squares method. The plausibility of each model was evaluated by calculating the Akaike information criterion
difference (AICc) and the Akaike weight (33, 34). The table shows the models in descending order (i.e. the most plausible model is listed first). The kinetic
parameters derived from the two most plausible inhibition models are presented in Table 2.
TABLE 2
Kinetic parameters describing interactions of PfCRTDd2 with chloroquine, quinine, and verapamil
Shown are the best-fit values of kinetic parameters obtained using the full and partial mixed-type inhibition models. The drug present in radiolabeled form was denoted as
the substrate, and the unlabeled drug was denoted as the inhibitor. CI, confidence interval; Vmax, the maximum velocity of substrate transport; KSCQ, KSQN, and KSVP, the
dissociation constants for the chloroquine-PfCRTDd2, quinine-PfCRTDd2, and verapamil-PfCRTDd2 complexes, respectively; 	, the factor by which these KS values change
when the opposing substrate is already bound to the transporter; , the factor by which the Vmax is affected by the inhibitor; CQ, chloroquine; QN, quinine; VP, verapamil.
Substrate Inhibitor Parameters
Mixed (full) Mixed (partial)
Mean  S.E. 95% CI Mean  S.E. 95% CI
CQ QN Vmax (pmol/oocyte/h) 33  2 29–37 33  2 29–37
KSCQ (M) 250  30 192–315 250  30 192–316
KSQN (M) 40  7 26–54 40  7 25–53
	 2.6  1 0.3–5 2.6  1 0.3–5
 0.02  0.03 0.04–0.1
QN CQ Vmax (pmol/oocyte/h) 9  0.2 9–10 9  0.2 9–10
KSQN (M) 25  1 22–28 25  1 22–28
KSCQ (M) 340  50 240–440 342  54 234–450
	 1.9  0.5 0.9–2.8 2  0.5 0.9–2.8
 0.00  0.03 0.05–0.05
CQ VP Vmax (pmol/oocyte/h) 27  0.3 26–27 27  0.3 26–27
KSCQ (M) 195  6 183–208 196  6 185–207
KSVP (M) 36  2 32–40 35  2 31–38
	 2.9  0.4 2–4 3  0.3 2–3
 0.03  0.01 0.01–0.05
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inhibition are rare in nature and appear to be primarily
restricted to small inhibitors, such as protons or other inor-
ganic ions (36). Given that chloroquine and quinine are large
organic compounds (both have molecular weights greater than
300 g/mol), it is unlikely that quinine is a noncompetitive inhib-
itor of chloroquine transport via PfCRT.
Mixed-type inhibition occurs when an inhibitor can bind to
an enzyme (or, in this case, a transporter) regardless of whether
the substrate-binding site is occupied or empty but exhibits
greater potency against one binding state over the other.
Mixed-type inhibitors affect the apparent affinity of the trans-
porter for the substrate (i.e. the Km) and also cause a decrease in
the apparent maximum rate of transport (i.e. the Vmax). Hence,
if quinine behaves as a mixed-type inhibitor of chloroquine
transport, we would expect it to affect both the apparent Km
and apparent Vmax of chloroquine transport via PfCRTDd2. To
test this possibility, we reanalyzed the data presented in Fig. 2A
by fitting the Michaelis-Menten equation to each of the seven
data sets (which differed in the concentration of quinine that
was present). The resulting apparent Vmax values as well as the
ratios of Vmax to Km were plotted as a function of the quinine
concentration (Fig. 3, A and B, respectively). Both of these val-
ues decreased with increasing concentrations of unlabeled qui-
nine, resulting in hyperbolic curves. The half-maximum inhib-
itory concentration derived from Fig. 3A, which equates to the
dissociation constant for the binding of quinine to the chloro-
quine-PfCRTDd2 complex (	KS (36)), was 120  25 M. By con-
trast, the half-maximum inhibitory concentration derived from
Fig. 3B (40  3 M) gives the dissociation constant for the bind-
ing of quinine to the empty transporter (KS). Taken together,
these data indicate that (i) the presence of chloroquine in the
substrate-binding site reduces the transporter’s affinity for qui-
nine by a factor (	) of 3, and (ii) although quinine’s inhibition
FIGURE 3. Secondary analyses of the inhibition of PfCRTDd2-mediated chlo-
roquine transport by quinine. The Michaelis-Menten equation was fitted to the
kinetic data shown in Fig. 2A to derive the apparent Km and apparent Vmax values
for chloroquine transport at each of the seven concentrations of quinine (QN). A,
The resulting apparent Vmax values were plotted as a function of the quinine
concentration and a rectangular hyperbolic equation fitted to the data. The dot-
ted line indicates the quinine concentration at which the Vmax for chloroquine
transport was half-maximal. This value is the dissociation constant for the binding
of quinine to the chloroquine-PfCRTDd2 complex (	KS
QN). B, the ratio of the appar-
ent Vmax to its corresponding apparent Km was plotted as a function of the qui-
nine concentration and a rectangular hyperbolic equation fitted to the data. The
dotted line indicates the quinine concentration at which the Vmax/Km ratio was
half-maximal. This value equates to the dissociation constant for the binding of
quinine to the empty transporter (KS
QN).
FIGURE 4. Kinetic analysis of the inhibition of PfCRTDd2-mediated quinine transport by chloroquine. A, the uptake of quinine (QN) into water-injected
oocytes and oocytes expressing PfCRTDd2 was measured at pH 6.0 and in the presence of a total extracellular quinine concentration (radiolabeled plus
unlabeled) of 1, 3, 5, 10, 25, 30, 50, 60, 75, or 100 M. At each of these quinine concentrations, the effects of seven concentrations of unlabeled chloroquine (CQ;
ranging from 0 to 3 mM) were tested. For each of the 70 treatments, the rate of quinine transport attributable to PfCRTDd2 was then calculated by subtracting
the rate measured in water-injected oocytes from that in oocytes expressing PfCRTDd2. Quinine uptake is shown as the mean  S.E. (error bars) of at least four
biological repeats, within which measurements were made from 10 oocytes/treatment. B, Sixteen different models of inhibition were globally fitted to the data
presented in A using the least-squares method. The plausibility of each model was evaluated by calculating the Akaike information criterion difference (AICc)
and the Akaike weight (33, 34). The table shows the models in descending order (i.e. the most plausible model is listed first). Kinetic parameters derived from
the two most plausible inhibition models are presented in Table 2.
Distinct but Linked Drug-binding Sites in PfCRT
DECEMBER 26, 2014 • VOLUME 289 • NUMBER 52 JOURNAL OF BIOLOGICAL CHEMISTRY 36343
 at A
ustralian N
ational U
niversity on January 29, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
of chloroquine transport is mostly a competitive process, there
is also an uncompetitive component (Table 2).
A complementary set of experiments was undertaken to
investigate the ability of chloroquine to inhibit quinine trans-
port via PfCRTDd2. In assays similar to those described above,
the uptake of radiolabeled quinine was measured in the pres-
ence of different concentrations of unlabeled quinine (ranging
from 0 to 100 M), and at each of these quinine concentrations,
the effects of seven concentrations of unlabeled chloroquine
(ranging from 0 to 3 mM) were measured. The 16 models of
inhibition were fitted to the resulting data (presented in Fig. 4A)
and ranked according to AICc and the Akaike weight (Fig. 4B).
These analyses suggested that the most plausible models were
again full mixed-type inhibition and partial mixed-type inhibi-
tion (AICc of 0 and 2.5, respectively; Fig. 4B), with an F-test
indicating that full mixed-type inhibition best described the
data (F  0; p 	 1015). Moreover, increasing the concentra-
tion of unlabeled chloroquine decreased the apparent Vmax of
quinine transport (Fig. 5A) and increased the apparent Km of
PfCRTDd2 for quinine (Fig. 5B). The corresponding 	KS and KS
values were 650  50 and 300  50 M, respectively. These
findings further support the idea that the affinity of PfCRTDd2
for one drug decreases when the carrier is occupied by a second
drug.
Having obtained complementary sets of kinetic parameters
for the transport of quinine and chloroquine via PfCRTDd2, as
well as of their inhibition of the transporter, we modeled the
kinetics of the interaction between PfCRTDd2, chloroquine and
quinine using the full mixed-type inhibition equation. Three-
dimensional plots of the modeled system are presented in Fig. 6,
A and B, with the experimentally derived data (from Fig. 2A or
4A, respectively) superimposed. To assess how well the model
fitted the data, we calculated the difference between the
observed and expected uptake values and plotted the resulting
residual values as a function of quinine or chloroquine concen-
tration (Fig. 6, C and D, respectively) (37). Within each concen-
tration of chloroquine or quinine, the residuals did not tend to
cluster to one side or the other of the x axis but were instead
randomly distributed across the x axis. This pattern indicates
that the model is an appropriate fit to the experimentally
derived data, thereby providing further evidence that full
mixed-type inhibition is a plausible model for the interaction of
PfCRTDd2 with chloroquine and quinine.
Distinct Binding Sites for Chloroquine and Quinine—Many
enzymes and some transporters bind substrates by induced fit,
whereby the binding of a substrate alters the conformation of
the protein (32, 38). If PfCRT functions according to an induced
fit mechanism, different substrates could induce distinct con-
formational changes, and even if the substrates compete for
binding at the same site, the differences between these confor-
mations may account for the mixed-type mechanism of inhibi-
tion identified here for chloroquine and quinine. To test
whether chloroquine and quinine bind to the same site or at
distinct sites, we performed the competition plot experiment
(35). To this end, we selected a concentration of chloroquine
(from the 0 M quinine treatment of Fig. 2A) and a quinine
concentration (from the 0 M chloroquine treatment of Fig. 4A)
that gave the same rate of drug transport (35). Measurements of
radiolabeled chloroquine or radiolabeled quinine were then
made in the presence of different proportions of these chloro-
quine and quinine concentrations (calculated using the equa-
tions set out under “Experimental Procedures”). For each of the
resulting chloroquine/quinine mixtures, the rate of PfCRT-me-
diated chloroquine and quinine transport was determined (in
fluxes performed pairwise) and then added together to yield a
“total” rate of drug transport. These rates were plotted as a
function of the proportion of quinine in the chloroquine/qui-
nine mixture (P). If two substrates bind to the same site, the
total rate of drug transport will be independent of P. However,
if the substrates bind to different but antagonistically interact-
ing sites, the total rate of drug transport will vary with P, result-
ing in a concave curve (35). Given that the latter relationship
was apparent for PfCRTDd2 (Fig. 7), it is unlikely that the mixed-
type inhibition kinetics observed for chloroquine and quinine
arise from a special case of product inhibition. This finding,
together with the analyses of the kinetics of inhibition, suggests
that there are distinct but interdependent binding sites within
PfCRTDd2 for chloroquine and quinine.
FIGURE 5. Secondary analyses of the inhibition of PfCRTDd2-mediated
quinine transport by chloroquine. The Michaelis-Menten equation was fit-
ted to the kinetic data shown in Fig. 4A to derive the apparent Km and appar-
ent Vmax values for quinine transport at each of the seven concentrations of
chloroquine (CQ). A, the resulting apparent Vmax values were plotted as a
function of the chloroquine concentration and a rectangular hyperbolic
equation fitted to the data. The dotted line indicates the chloroquine concen-
tration at which the Vmax for quinine transport was half-maximal. This value is
the dissociation constant for the binding of chloroquine to the quinine-
PfCRTDd2 complex (	KS
CQ). B, the ratio of the apparent Vmax to its correspond-
ing apparent Km was plotted as a function of the chloroquine concentration
and a rectangular hyperbolic equation fitted to the data. The dotted line indi-
cates the chloroquine concentration at which the Vmax/Km ratio was half-
maximal. This value equates to the dissociation constant for the binding of
chloroquine to the empty transporter (KS
CQ). Error bars, S.E.
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Verapamil Acts as a Partial Mixed-type Inhibitor of
PfCRTDd2-mediated Chloroquine Transport—Verapamil is an
inhibitor of PfCRTDd2 and a reverser of chloroquine resistance
in vitro (7, 24, 30). At present, the clinical application of resis-
tance reversers (such as verapamil) has been prevented by prob-
lems with potency and host toxicity. Little is known about the
mechanism by which verapamil inhibits PfCRTDd2, yet it is pos-
sible that an understanding of this interaction could lead to the
development of more potent inhibitors of the transporter. We
investigated the interaction between verapamil and PfCRTDd2
by conducting substrate competition experiments similar to
those described for quinine and chloroquine. The PfCRT-me-
diated uptake of radiolabeled chloroquine was measured at five
different concentrations of unlabeled chloroquine (0, 50, 100,
300, and 500 M), and at each of these chloroquine concentra-
tions, the effects of six concentrations of unlabeled verapamil
(0, 15, 30, 100, 200, and 400 M) were tested (Fig. 8A). The data
were analyzed as outlined for the quinine and chloroquine data
sets, and the results are presented in Fig. 8B. A partial mixed-
type inhibition model was found to describe the data with high
statistical confidence (AICc of 0 and Akaike weight of 0.889),
and an F-test confirmed that this model was preferred over full
mixed-type inhibition (AICc of 4.16 and Akaike weight of
0.111; F  5.6, p 	 105). Increasing the concentration of unla-
beled verapamil decreased the apparent Vmax of chloroquine
transport (Fig. 9A) and increased the apparent Km of PfCRTDd2
for chloroquine (Fig. 9B), with the verapamil 	KS for the chlo-
roquine-PfCRT complex (110  10 M) 3-fold greater than
the verapamil KS for the empty transporter (35  4 M). Finally,
we evaluated the partial mixed-type inhibition model by super-
imposing the experimentally derived data over a three-dimen-
sional plot of the modeled system (Fig. 9C). A plot of the resid-
ual values as a function of the chloroquine or verapamil
concentration (Fig. 9D) produced, in both cases, a relatively
random distribution of points across the x axis. These results
suggest that verapamil acts as a partial mixed-type inhibitor of
chloroquine transport via PfCRTDd2.
The ability of PfCRTDd2 to translocate verapamil was inves-
tigated by measuring the uptake of radiolabeled verapamil in
water-injected oocytes and in oocytes expressing PfCRTDd2 or
FIGURE 6. Modeling the interaction between PfCRTDd2, chloroquine, and quinine using the full mixed-type inhibition equation. To test how well the full
mixed-type inhibition model fitted the kinetic data presented in Figs. 2A and 4A, the relevant equation was solved using the kinetic parameters for the transport
of quinine (QN) and chloroquine (CQ) via PfCRTDd2 as well as of their inhibition of the transporter. The resulting predicted values (red lines) were then displayed
as a three-dimensional plot, with the experimentally derived data shown for comparison. A, inhibition of chloroquine transport by quinine. The following
values were used: Vmax  33 pmol of chloroquine/h/oocyte; chloroquine concentrations  0 –500 M; chloroquine KS
CQ  270 M; quinine KS
QN  32 M; quinine
concentrations  0 –500 M; 	  2.5. B, inhibition of quinine transport by chloroquine. The following values were used: Vmax  9.6 pmol of quinine/h/oocyte;
quinine concentration  0 –100 M; quinine KS
QN  32 M; chloroquine KS
CQ  270 M; chloroquine concentrations  0 –3000 M; 	  2.5. C and D, in accordance
with the analysis described by Cornish-Bowden (37), the difference between the experimentally derived data and the predicted values was calculated, and the
resulting residuals are displayed as a function of (i) the chloroquine concentration and (ii) the quinine concentration.
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PfCRTHB3. As shown in Fig. 10, there was a modest but statis-
tically significant increase in the accumulation of verapamil in
oocytes expressing PfCRTDd2 relative to water-injected oocytes
or oocytes expressing PfCRTHB3. The low signal obtained for
the transport of verapamil via PfCRTDd2, which is most likely
due to the relatively high lipophilicity of this drug (at pH 5.2
verapamil has a distribution coefficient (log D) of 0.52, whereas
chloroquine has a log D of 3.44; (39)), precluded a kinetic
analysis of verapamil transport.
DISCUSSION
Here we provide direct evidence for the transport of quinine,
quinidine, and the resistance reverser verapamil via PfCRTDd2.
By contrast, these drugs do not appear to be substrates of the
wild-type form of the protein (PfCRTHB3). These observations
are consistent with the findings of Lehane et al. (19, 21) as well
as those of Wellems and colleagues (22, 23). The former studies
showed that chloroquine, quinine, quinidine, and verapamil are
each able to induce a proton leak from the digestive vacuole of
parasites carrying PfCRTDd2 but not from the digestive vacuole
of an isogenic line expressing PfCRTHB3. In the work performed
by Wellems and co-workers, the accumulation of chloroquine,
quinine and quinidine was reduced in D. discoideum cells
expressing PfCRTDd2 at the endosomal membrane but was
unchanged in the cell line expressing PfCRTHB3. Moreover,
intact endosomes isolated from the PfCRTDd2-expressing cells
were also shown to accumulate less chloroquine and quinine
compared with endosomes extracted from untransformed cells
or cells expressing PfCRTHB3. Hence, there is now an apprecia-
ble body of evidence, obtained from three different experimen-
tal systems, which indicates that PfCRTDd2 is not just a trans-
porter of chloroquine but may be viewed as a “multidrug
resistance carrier.”
FIGURE 7. Competition plot of the interaction of PfCRTDd2 with chloro-
quine and quinine. The competition plot tests whether two reactions occur
at the same site or at distinct sites (35). An extracellular concentration of
quinine (73.5 M) was selected from the data presented in Fig. 4A, such that
the resulting rate of quinine transport (7.4 pmol/h/oocyte) would approach
its Vmax. The concentration of chloroquine (52.1 M) that would result in the
equivalent rate of chloroquine transport was estimated from the data shown
in Fig. 2A. Pairwise measurements of radiolabeled chloroquine and radiola-
beled quinine were made in the presence of different proportions of these
chloroquine and quinine concentrations (see “Experimental Procedures”),
from which the total rate of drug transport within each of the chloroquine/
quinine mixtures was calculated. The resulting total PfCRTDd2-mediated
transport velocities (Vtotal) were plotted as a function of the proportion of
quinine in the chloroquine/quinine mixture (P). The total rate of drug uptake
(closed circles) is shown as the mean  S.E. (error bars) of four biological
repeats, within which measurements were made from 10 oocytes/treatment.
If the two drugs compete for binding to the same site, the total rate of drug
transport within each of the chloroquine/quinine mixtures would be 7.4
pmol/h/oocyte (indicated by the solid line). By contrast, if chloroquine and
quinine bind to distinct but antagonistically interacting sites, the total rate of
drug transport will vary with P, resulting in a concave curve (open circles;
values were predicted as described under “Experimental Procedures” using a
full mixed-type inhibition model). Those experiments in which P equaled
0.15, 0.40, 0.60, or 0.9 yielded rates that were significantly different from 7.4
pmol/h/oocyte (p 	 0.01; one-way analysis of variance).
FIGURE 8. Kinetic analysis of the inhibition of PfCRTDd2-mediated chloroquine transport by verapamil. A, the uptake of chloroquine (CQ) into water-
injected oocytes and oocytes expressing PfCRTDd2 was measured at pH 6.0 and in the presence of a total extracellular chloroquine concentration (radiolabeled
plus unlabeled) of 10, 50, 100, 300, or 500 M. At each of these chloroquine concentrations, the effects of six concentrations of unlabeled verapamil (VP; ranging
from 0 to 400 M) were tested. For each of the 30 treatments, the rate of chloroquine transport attributable to PfCRTDd2 was then calculated by subtracting the
rate measured in water-injected oocytes from that in oocytes expressing PfCRTDd2. Chloroquine uptake is shown as the mean  S.E. (error bars) of at least eight
biological repeats, within which measurements were made from 10 oocytes/treatment. B, Sixteen different models of inhibition were globally fitted to the data
presented in A using the least-squares method. The plausibility of each model was evaluated by calculating the Akaike information criterion difference (AICc)
and the Akaike weight (33, 34). The table shows the models in descending order (i.e. the most plausible model is listed first). The kinetic parameters derived from
the two most plausible inhibition models are presented in Table 2.
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Our detailed kinetic analyses of PfCRT-mediated drug trans-
port in the presence of a second (inhibiting) drug indicated that
these drugs interact with PfCRTDd2 in a complex manner. In
three separate sets of experiments (Figs. 2, 4, and 8), the inter-
actions of chloroquine, quinine, and verapamil with PfCRTDd2
were best explained by models of mixed-type inhibition. This
form of inhibition, which combines features of both competi-
tive and uncompetitive inhibition, is characterized by system-
atic variations in the Km and Vmax for the transport of one sub-
strate in the presence of a second substrate. In all three
experiments, occupation of PfCRTDd2 by one drug reduced the
protein’s affinity for the second drug by a factor of 2–3, a finding
that is consistent with the drugs acting to compete with one
another’s transport. However, the binding of one drug did not
fully exclude the binding of the second, and the binding of both
drugs to PfCRTDd2 led to the formation of a ternary complex,
the properties of which differed depending on the substrates
that were bound. In the case of chloroquine and quinine, the
value derived for the parameter  (a measure of the contribu-
tion of the chloroquine-quinine-PfCRTDd2 complex to the total
rate of transport), was not different from zero (Table 2). This
finding indicates that the binding of both chloroquine and qui-
FIGURE 9. Secondary analyses and modeling of the inhibition of PfCRTDd2-mediated chloroquine transport by verapamil. A, the Michaelis-Menten
equation was fitted to the kinetic data shown in Fig. 8 to derive the apparent Km and apparent Vmax values for chloroquine (CQ) transport at each of the six
concentrations of verapamil (VP). The resulting apparent Vmax values were plotted as a function of the verapamil concentration and a rectangular hyperbolic
equation fitted to the data. The dotted line indicates the verapamil concentration at which the Vmax for chloroquine transport was half-maximal. This value is the
dissociation constant for the binding of verapamil to the chloroquine-PfCRTDd2 complex (	Ks
VP). B, the ratio of the apparent Vmax to its corresponding apparent
Km was plotted as a function of the verapamil concentration and a rectangular hyperbolic equation fitted to the data. The dotted line indicates the verapamil
concentration at which the Vmax/Km ratio was half-maximal. This value equates to the dissociation constant for the binding of verapamil to the empty
transporter (Ks
VP). C, the partial mixed-type inhibition equation was solved using the following values: Vmax  26 pmol of chloroquine/h/oocyte; chloroquine
concentrations  0 –500 M; chloroquine KS  270 M; verapamil Ks
VP  36 M; verapamil concentrations  0 – 400 M; 	  2.5;   0.03. The resulting
predicted values (red lines) were then displayed as a three-dimensional plot, with the experimentally derived data shown for comparison. D, in accordance with
the analysis described by Cornish-Bowden and co-workers (35), the difference between the experimentally derived data and the predicted values was
calculated, and the resulting residuals were displayed as a function of (i) the chloroquine concentration and (ii) the verapamil concentration.
FIGURE 10. The transport of verapamil into Xenopus oocytes expressing
PfCRT. A, the uptake of verapamil was measured in water-injected control
oocytes and oocytes expressing PfCRTHB3 or PfCRTDd2 over an extracellular
pH range of 4.0 –5.0. The total concentration of verapamil (radiolabeled plus
unlabeled) was 5 M. Uptake is shown as the mean  S.E. (error bars) of three
biological repeats, within which measurements were made from 10 oocytes/
treatment. Asterisks indicate significant differences in the accumulation of
verapamil between the control (water-injected or PfCRTHB3-expressing)
oocytes and oocytes expressing PfCRTDd2 within each pH condition (*, p 	
0.05). B, the percentages of verapamil in the neutral (VP) and monoproto-
nated (VP) forms in solutions of different pH. The percentages were calcu-
lated using the Henderson-Hasselbalch equation with a pKa value of 8.92 (52).
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nine to PfCRTDd2 results in an inactive transporter and that the
kinetic data are therefore better described by full mixed-type
inhibition rather than partial mixed-type inhibition (Fig. 2B).
By comparison, analyses of the kinetics of verapamil inhibition
suggested that the verapamil-chloroquine-PfCRTDd2 complex
remains active, albeit with a chloroquine transport rate that is
30-fold lower than that measured in the absence of verapamil
(  0.03  0.01; Table 2). Hence, partial mixed-type inhibition
was found to be more plausible than full mixed-type inhibition
for modeling the inhibition of chloroquine transport by vera-
pamil (Fig. 8B). The very low level of activity detected for the
verapamil-chloroquine-PfCRTDd2 complex suggests that the
transporter is occasionally able to translocate chloroquine and
verapamil in symport, which is a phenomenon that is unlikely
to occur when chloroquine and quinine are the bound sub-
strates. The reaction schemes describing the interactions of
PfCRTDd2 with (i) chloroquine and quinine and (ii) chloroquine
and verapamil are shown in Fig. 11, A and B, respectively.
Very few studies have attempted to elucidate the mechanism
by which resistance-conferring forms of PfCRT interact with
different substrates or inhibitors. In a detailed analysis of struc-
ture-activity relationships among a series of chemosensitizing
agents, Alibert et al. (26) predicted the features of a putative
drug-binding site that would account for the patterns of resis-
tance-reversing activity that they observed. The authors sug-
gested that the amino groups present in many quinoline anti-
malarials and reversing agents (including chloroquine and
verapamil) would form hydrogen bonds with a hydroxyl group
of a serine and a salt bridge with the carboxyl group of an aspar-
tic acid. They proposed that the N75E and K76T mutations in
PfCRTDd2, (which introduce a glutamate and a threonine resi-
due, respectively) could fulfill these roles, forming a site of
interaction where compounds compete for binding and trans-
location (26, 27). Studies of laboratory-derived drug-resistant
parasites as well as of transgenic lines that differ in the haplo-
type of PfCRT they carry have provided good support for the
idea that position 76 plays a crucial role in determining the
susceptibility of the parasite to chloroquine and quinine (11, 28,
29). Indeed, we recently showed that the minimum changes
required to enable PfCRT to transport chloroquine are K76T
with either N75E or N326D (25). When considered together,
these observations suggest that the threonine at position 76 is
the key element of the binding site of resistance-conferring
forms of PfCRT. However, the results of our kinetic analyses
indicate that interactions at a single site are not sufficient to
explain the complex interplay observed between PfCRTDd2 and
chloroquine, quinine, and verapamil. In regard to chloroquine
and quinine, the mixed-type inhibition observed for these two
substrates could not be attributed to a special case of product
inhibition, and the results of the competition plot confirmed
that these two drugs do not compete for binding at a single site.
The lack of a robust signal for the uptake of verapamil via
PfCRTDd2 precluded a similar examination of the interplay
between chloroquine and verapamil. Nevertheless, the finding
that the partial mixed-type model best describes the inhibition
of PfCRTDd2 by verapamil suggests that chloroquine and
verapamil are also likely to be binding to distinct sites. Taken
together, our studies suggest that a more nuanced model is
required to describe the interaction of PfCRTDd2 with its
substrates.
We recently showed that several of the eight mutations
found in PfCRTDd2 demonstrate epistasis and that the protein
acquires the ability to transport chloroquine via a rigid process
(whereby mutations must be added in a specific order to avoid
significant reductions in chloroquine transport activity) (25).
These findings indicate that the repurposing of PfCRT for the
binding and translocation of chloroquine entails dramatic and
complex rearrangements to its substrate-binding site (25). The
work presented here suggests that these changes have also
modified the transporter’s ability to interact with related drugs
(quinine and quinidine) as well as a relatively different pharma-
con (verapamil). Bearing this in mind and given that our data
FIGURE 11. Proposed reaction schemes describing the interaction of
PfCRTDd2 with chloroquine, quinine and verapamil. A, chloroquine (CQ)
and quinine (QN) act as full mixed-type inhibitors of PfCRTDd2-mediated
transport. PfCRTDd2 can bind chloroquine and quinine at distinct sites. The
ternary complex (ToQNoCQo) is inactive. To represents PfCRT
Dd2 in the out-
ward facing conformation (i.e. the extracellular face of the protein when in the
oocyte plasma membrane and its luminal face when in the membrane of the
digestive vacuole), and Ti represents PfCRT
Dd2 in the inward facing conforma-
tion (i.e. the cytosolic face of the protein when in the membrane of either the
oocyte or the digestive vacuole). Likewise, CQo and QNo are the extracellular/
lumenal drug concentrations, and CQi and QNi are the cytosolic drug concen-
trations. KS
CQ and KS
QN are the respective quinine and chloroquine dissociation
constants for PfCRTDd2; 	 is the factor by which KS
CQ and KS
QN change when the
other drug is already bound to the transporter; and kcat
CQ and kcat
QN describe the
rate constants of chloroquine and quinine transport. B, chloroquine and
verapamil (VP) act as partial mixed-type inhibitors of PfCRTDd2-mediated
transport. The ternary complex (ToVPoCQo) retains a low level of activity. VPo
and VPi are the extracellular/lumenal and cytosolic concentrations of vera-
pamil, respectively. KS
VP is the verapamil dissociation constant for PfCRTDd2; 	
is the factor by which KS
CQ and KS
VP change when the other drug is already
bound to the transporter; kcat
VP describes the rate constant of verapamil trans-
port; and  is the factor by which verapamil and chloroquine affect the rate
constant of the other drug’s transport.
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indicate that PfCRT possesses distinct binding sites for chloro-
quine and quinine (and for chloroquine and verapamil), it is
possible that the mutations required for chloroquine resistance
have enlarged the protein’s substrate-binding site by creating
new substrate interaction points and/or multiple binding pock-
ets. A large drug-binding cavity consisting of different substrate
interaction domains has been observed in several other mem-
brane transport proteins, including the multidrug resistance
P-glycoprotein and the organic cation transporters (40 – 43).
There are several ways in which the binding of a drug at one
pocket of PfCRTDd2 could influence the properties of other
substrate-binding sites. First, the binding of one substrate could
result in conformational changes that alter the protein’s ability
to bind a substrate at a second site. This allosteric mechanism is
consistent with the induced fit model of protein function,
which has been remarkably successful in explaining the func-
tions of a range of proteins, including transporters and channels
(44). Our observations could also be reconciled with a slightly
different scenario in which chloroquine and other compounds
interact with several points of attachment within a large sub-
strate-binding cavity. If one or more of these points of attach-
ment are used by both of the substrates, then binding could be
partial or reduced in affinity or could result in a shift in location
of one substrate by the other, and it may even fail to trigger
translocation. In this regard, it is worth noting that partially
overlapping binding sites are often found in cases of mixed-type
inhibition (43, 45, 46).
A third mechanistic explanation for the effect of a bound
drug on a second binding site comes from the observation that
PfCRTDd2 appears to transport drugs in their mono- and/or
diprotonated forms (24) (Figs. 1A and 10B). The attachment of
a protonated drug would add one or more positive charges to
the protein’s substrate-binding cavity, resulting in a reduction
in the electrostatic attractions between this domain and the
second protonated drug. In this regard, it is worth noting that of
the eight amino acids that differ between PfCRTHB3 and
PfCRTDd2, four result in the gain of a negative charge or the loss
of a positive charge (N75E, K76T, Q271E, and R371I). Hence, it
is highly likely that electrostatic interactions play an important
role in the transport activity of PfCRTDd2. This electrostatically
driven model of inhibition is similar to the one proposed by
Warhurst (39), who suggested that verapamil (in its protonated
form) reduces the transport of chloroquine via PfCRTDd2 by
restoring the positive charge that was removed by the K76T
mutation.
Our findings have a number of implications for the design
and development of new antimalarial drugs and strategies. We
have recently shown that the transport of chloroquine via a
wide range of resistance-associated isoforms of PfCRT is satu-
rable, and, in parasites exposed to a standard clinical dose of
chloroquine, the transporter would already be operating at or
near maximum capacity (25). These observations, together
with a recent clinical trial that revealed that “double dose” chlo-
roquine is as effective as the current gold standard antimalarial
(artemether-lumefantrine) in treating P. falciparum infections
in the Republic of Guinea-Bissau (47), have raised the very real
possibility that chloroquine-resistant malaria from regions
around the world could likewise be treated by a revised dosage
of the drug. The work presented here has extended these obser-
vations by demonstrating that the transport of quinine and
quinidine via PfCRTDd2 is also saturable. This finding adds fur-
ther support to the view that PfCRTDd2 behaves as a multidrug
resistance carrier rather than as a channel. Moreover, it may
explain, at least in part, why revisions of the quinine dose regi-
men (which have entailed increases in the quantity of quinine
per dose, the frequency of administration, and/or the duration
of the course) have largely resulted in significantly improved
cure rates in regions where drug-resistant malaria is prevalent
(reviewed in Ref. 48). Hence, it is becoming increasingly appar-
ent that the saturability of drug transport via PfCRT is likely to
represent a potential “Achilles’ heel” of the quinoline resistance
mechanism and that antimalarial drugs (existing and future) for
which clinical efficacy is compromised by mutations in PfCRT
may be restored to efficacy by using reoptimized dosages.
The results of our kinetic analyses also indicate that different
drugs are likely to interact with distinct sites within a polyspe-
cific substrate recognition cavity of PfCRTDd2, resulting in dif-
ferent levels of affinity and transport efficiency. This suggests
that there may be scope for the interaction of an antimalarial
drug with PfCRTDd2 to be minimized or even eliminated with
modest modifications to its structure, thus allowing the drug to
escape the resistance mechanism altogether. In other cases, it
may be desirable to increase and optimize the interactions
between PfCRTDd2 and a drug. For instance, a clinically effec-
tive reverser of chloroquine resistance is likely to be a drug that
occupies multiple sites within the PfCRTDd2 substrate-binding
cavity, because increasing the number of attachment points
between the inhibitor and the transporter should increase the
affinity of binding. Furthermore, once an inhibitor of this type is
bound to the protein at one site, the probability of another part
of the molecule binding to a second site is substantially
increased relative to two separate compounds binding to the
same sites (49). In this regard, it is interesting to note that a
series of quinine dimers have recently been reported as the
most potent inhibitors of PfCRTDd2 identified to date (50).
These compounds inhibited the PfCRTDd2-mediated transport
of chloroquine into Xenopus oocytes with half-maximum
inhibitory concentrations between 1 and 6 M. These values are
substantially lower than that measured for the quinine mono-
mer (48  3 M (24)). Moreover, the quinine dimers were not
substrates of PfCRTDd2, and their strong affinity for the trans-
porter translated into potent resistance-reversing activity.
For example, low nanomolar concentrations of a quinine
dimer restored the activity of chloroquine against chloro-
quine-resistant parasites, whereas micromolar concentrations
were required for verapamil to exert an effect. The potent activ-
ity of the quinine dimers against PfCRTDd2 is probably due to
their occupation of more than one site within the transporter’s
substrate-binding cavity.
The work described here provides direct evidence of the abil-
ity of a chloroquine resistance-conferring form of PfCRT to
transport quinine, quinidine, and verapamil. In a series of
detailed kinetic analyses, we showed that chloroquine and qui-
nine and also chloroquine and verapamil are mixed-type inhib-
itors of one another. The patterns of inhibition that we
observed indicate that PfCRTDd2 possesses more than one
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drug-binding site and that these binding sites, although dis-
tinct, are interdependent and hence may be located within a
large polyspecific substrate recognition cavity. Our findings
suggest that the mutations that confer resistance to chloro-
quine allow the protein to interact with and transport a range of
structurally diverse compounds. However, the additional sub-
strate attachment points generated by these changes could be
exploited for the design of potent resistance-reversing agents.
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